1 Min Read
Oct 23 (Reuters) - Alexion Pharmaceuticals Inc:
* FDA approves soliris® (eculizumab) for the treatment of patients with generalized myasthenia gravis (gmg) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.